WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530402

CAS#: 1114561-85-1

Description: BI-135585 is a potent and selective 11β-HSD1 inhibitor. BI 135585 was safe and well tolerated over 14 days and can be dosed once daily.

Price and Availability




BI-135585 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 530402
Name: BI-135585
CAS#: 1114561-85-1
Chemical Formula: C28H32N2O4
Exact Mass: 460.2362
Molecular Weight: 460.574
Elemental Analysis: C, 73.02; H, 7.00; N, 6.08; O, 13.89

Synonym: BI-135585; BI 135585; BI135585.

IUPAC/Chemical Name: (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one


InChi Code: InChI=1S/C28H32N2O4/c1-20(21-10-12-22(13-11-21)23-14-16-29(4)25(31)18-23)30-17-15-28(34-26(30)32,19-27(2,3)33)24-8-6-5-7-9-24/h5-14,16,18,20,33H,15,17,19H2,1-4H3/t20-,28-/m0/s1

SMILES Code: O=C1O[C@](C2=CC=CC=C2)(CC(C)(O)C)CCN1[C@H](C3=CC=C(C(C=CN4C)=CC4=O)C=C3)C

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Freude S, Heise T, Woerle HJ, Jungnik A, Rauch T, Hamilton B, Schölch C, Huang
F, Graefe-Mody U. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a
selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver
and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations
over 2 weeks. Diabetes Obes Metab. 2016 May;18(5):483-90. doi: 10.1111/dom.12635.
PubMed PMID: 26799632.

2: Hamilton BS, Himmelsbach F, Nar H, Schuler-Metz A, Krosky P, Guo J, Guo R,
Meng S, Zhao Y, Lala DS, Zhuang L, Claremon DA, McGeehan GM. Pharmacological
characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor,
BI 135585, a clinical candidate for the treatment of type 2 diabetes. Eur J
Pharmacol. 2015 Jan 5;746:50-5. doi: 10.1016/j.ejphar.2014.10.053. PubMed PMID: